Innoscripta SE

Innoscripta SE forecasts 2026 revenue of €140 M and EBIT of €80 M, bolstering confidence in its cloud‑based compliance platform and stable order pipeline.

Innoscripta SE plans a €4.00 dividend, signaling strong margins and confident growth despite tech sell‑off—investors watch its upcoming meeting for confirmation.

Innoscripta SE’s 2025 results show a 69 % EBIT margin and a sharp share rally, yet executive transactions raise governance questions for investors.

Innoscripta SE is a leading provider of cloud-based compliance software for research and development, offering innovative solutions that streamline the R&D process and ensure compliance with funding requirements.

Innoscripta SE, a company listed on the Frankfurt Stock Exchange, is experiencing a challenging period following its IPO, with its share price declining from a 52-week high of 120 EUR to 85.6 EUR, prompting founders to intervene with selective share…

The founders of Innoscripta SE plan to purchase up to €12 million in shares to support the company’s stock price, which has hit a 52-week low.

Innoscripta SE is poised for a potential revenue boost as the German government’s draft bill proposes changes to the R&D tax incentive scheme, which could significantly increase funding and revenue for the biotech company.